Re: “Prediction of skeletal-related events in patients with non-small cell lung cancer”—use of Spine Instability Neoplastic Score (SINS)

被引：0
|
作者：
Estanislao Arana
Francisco M. Kovacs
Ana Royuela
Beatriz Asenjo
Úrsula Pérez-Ramírez
Javier Zamora
机构：
[1] Valencian Oncology Institute Foundation,Department of Radiology
[2] Research Institute in Health Services Foundation,Spanish Back Pain Research Network
[3] Kovacs Foundation,Spanish Back Pain Research Network
[4] Unidad de la Espalda Kovacs,UGC de Radiología
[5] Hospital Universitario Moncloa,Center for Biomaterials and Tissue Engineering
[6] CIBER Epidemiology and Public Health (CIBERESP),Barts and the London School of Medicine & Dentistry
[7] Complejo Hospitalaria Universitario de Granada,undefined
[8] Universitat Politècnica de València,undefined
[9] Clinical Biostatistics Unit Hospital Ramón y Cajal,undefined
[10] IRYCIS,undefined
[11] Queen Mary University of London,undefined
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Bone Metastasis; Assessment Tool; Radiation Oncologist; Medical Oncologist; Routine Clinical Practice;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3273 / 3274
页数：1
相关论文
共 50 条
  • [21] Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer
    Huang, Shu-Mei
    Yang, Jin-Ji
    Chen, Hua-Jun
    Wu, Si-Pei
    Bai, Xiao-Yan
    Zhou, Qing
    Tu, Hai-Yan
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (46) : 81369 - 81376
  • [22] Correlations between disease progression and risk of Skeletal-Related Events (SREs) in patients with Bone Metastases (BM) from Non-Small Cell Lung Cancer (NSCLC) and other solid tumors
    Tchekmedyian, Simon N.
    Chen, Yin-Miao
    Hirsh, Vera
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S683 - S684
  • [23] Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events
    Yaldo, Avin
    Wen, Lonnie
    Ogbonnaya, Augustina
    Valderrama, Adriana
    Kish, Jonathan
    Eaddy, Michael
    Kreilick, Charles
    Tangirala, Krishna
    Shields, Katarzyna
    CLINICAL THERAPEUTICS, 2016, 38 (08) : 1880 - 1889
  • [24] Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial
    Hirotaka Miyashita
    Christina Cruz
    Cardinale Smith
    Supportive Care in Cancer, 2021, 29 : 1629 - 1633
  • [25] Bone disease progression (BDP) is associated with significantly increased risk of skeletal-related events (SREs) in patients with advanced solid tumors including non-small cell lung cancer (NSCLC)
    Tchekmedyian, Simon N.
    Chen, Yin-Miao
    Hirsh, Vera
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S543 - S543
  • [26] Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients
    Chayangsu, Chawalit
    Khorana, Jiraporn
    Charoentum, Chaiyut
    Sriuranpong, Virote
    Patumanond, Jayanton
    Tantraworasin, Apichat
    HEALTHCARE, 2023, 11 (03)
  • [27] The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer
    Delea, T
    Langer, C
    McKiernan, J
    Liss, M
    Edelsberg, J
    Brandman, J
    Sung, J
    Raut, M
    Oster, G
    ONCOLOGY, 2004, 67 (5-6) : 390 - 396
  • [28] Proteomics score: a potential biomarker for the prediction of prognosis in non-small cell lung cancer
    Peng, Jie
    Zhang, Jing
    Zou, Dan
    Gong, Wuxing
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 1904 - +
  • [29] Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial
    Miyashita, Hirotaka
    Cruz, Christina
    Smith, Cardinale
    SUPPORTIVE CARE IN CANCER, 2021, 29 (03) : 1629 - 1633
  • [30] Osimertinib related cardiotoxicity in patients with non-small cell lung cancer
    Mensah, Samuel Akaakole
    Alruwaili, Waleed
    Ahmad, Syed
    Patel, Brijesh
    Almubarak, Mohammed
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345